Share on LinkedInShare on LinkedIn

ARTICLE · 27 FEBRUARY 2026

2025 In Review: Analyzing Hatch-Waxman Litigation Trends

Our latest Hatch-Waxman report, Analyzing Hatch-Waxman Litigation Trends: 2025 in Review, delivers a data-driven examination of ANDA litigation, grounded in our systematic...

United StatesLitigation, Mediation & Arbitration

Our latest Hatch-Waxman report, Analyzing Hatch-Waxman Litigation Trends: 2025 in Review, delivers a data-driven examination of ANDA litigation, grounded in our systematic tracking of Paragraph IV challenges and corresponding Orange Book products. This year's review—covering 320 new ANDA cases across 124 distinct product groups—highlights evolving venue dynamics, judicial exposure to recurring technical issues, and the portfolio strategies that shaped Hatch-Waxman litigation in 2025.

To ensure analytical precision beyond automated database classifications, we manually reviewed each pharmaceutical-related complaint, identifying actions initiated by both NDA holders and ANDA filers. We evaluated these cases for overall volume and substantive litigation patterns, providing practical insight for stakeholders navigating complex Hatch-Waxman disputes.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from